Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis
- 23 May 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (3), 265-272
- https://doi.org/10.1016/j.clcc.2021.05.006
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver ResectionClinical Colorectal Cancer, 2013
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast CancerThe New England Journal of Medicine, 2012
- Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasisHistopathology, 2010
- Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOXAnnals of Surgical Oncology, 2010
- Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomasLaboratory Investigation, 2009
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaThe New England Journal of Medicine, 1990
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986